Hyper‐ CVAD and Modified CALGB ‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14381 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Jessica Zalapa-Soto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objective
Acute lymphoblastic leukemia (ALL) has a higher incidence in Latin America, with adult patients experiencing worse long‐term outcomes despite high complete remission (CR) rates. When treated with adult regimens, 3‐year overall survival (OS) is approximately 20%. However, adopting pediatric‐inspired regimens (PIRs) has shown improved outcomes.
Methods
We performed a comparative analysis of Hispanic adult patients with newly diagnosed Ph‐negative ALL, treated with either a PIR, a modified CALGB 10403 (mCALGB), or the adult regimen Hyper‐CVAD between January 2015 and May 2023. The primary endpoint was OS and among secondary endpoints relapse‐free survival (RFS).
Results
We included 100 patients, 35 were treated with Hyper‐CVAD and 65 with mCALGB. Median age was 26 years (range, 20.2–38). The median OS was 54.2 months (95% CI 28.3–80.1), with a non‐reached median OS in the mCALGB group (95% CI NR‐NR) versus 22.4 months (95% CI 13.7–31) for Hyper‐CVAD. The 3‐year OS was 64.9% versus 34.9%, p = 0.034. Treatment with mCALGB was independently associated with OS (HR 0.29, 95% CI 0.13–0.66, p = 0.003) and RFS (HR 0.29, 95% CI 0.14–0.59, p < 0.001).
Conclusions
Treatment with mCALGB was independently associated with benefits regarding RFS and OS when compared to Hyper‐CVAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology and Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Internal Medicine Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Transfusion Medicine Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
ORCID-Profile: Fausto Alfredo Rios-Olais, Juan Rangel-Patiño, Roberta Demichelis-Gómez
Zitieren
APA
Zalapa-Soto, J., Rios-Olais, F. A., Chacón-Rangel, L. C., Mora-Cañas, A., Meza-Meza, M., Rangel-Patiño, J., & Demichelis-Gómez, R. (2025). Hyper‐ CVAD and Modified CALGB ‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study. European Journal of Haematology. https://doi.org/10.1111/ejh.14381
Vancouver
Zalapa-Soto J, Rios-Olais FA, Chacón-Rangel LC, Mora-Cañas A, Meza-Meza M, Rangel-Patiño J, et al. Hyper‐ CVAD and Modified CALGB ‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study. European Journal of Haematology. 2025. doi:10.1111/ejh.14381
BibTeX
@article{ZalapaSoto2025,
author = {Zalapa-Soto, Jessica and Rios-Olais, Fausto Alfredo and Chacón-Rangel, Lyam Carlo and Mora-Cañas, Analy and Meza-Meza, Mario and Rangel-Patiño, Juan and Demichelis-Gómez, Roberta},
title = {Hyper‐ CVAD and Modified CALGB ‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14381}
}
EUVIMED